Radium-223 in metastatic castration resistant prostate cancer
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals. However, from 2010 onwards, 5 additional therapies have been approved on the basis of showing a survival benefit in phase III...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications & Media Pvt Ltd
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023358/ |